Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats

I. Gera, J. M. Hock, M. Gunness-Hey, J. Fonseca, L. G. Raisz

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Chronic administration of parathyroid hormone, hPTH 1-34, increased bone mass in normocalcemic, young rats [6]. Since PTH can stimulate prostaglandin E2 (PGE2) production in bone in vitro, and since PGE2 can stimulate bone formation, the anabolic effect of PTH could be mediated by PGE2. To test this hypothesis, experiments were done to determine if indomethacin, which blocks endogeneous PG production, would inhibit the anabolic response of bone to PTH. In the first experiment, male Sprague-Dawley rats, 70-100 g, in groups of five, were treated for 12 days with either hPTH 1-34, 8 μg/100g/day; PTH vehicle; indomethacin, 2 mg/kg/day; or a combination of PTH and indomethacin. In the second experiment, groups of 6 rats each were given vehicle or hPTH 1-34, 8 μg/100g/day, in combination with indomethacin, 0, 1, 2, or 4 mg/kg/day. Subcutaneous injections of PTH were given once daily and indomethacin was given orally in divided doses, twice a day. Rats were killed on day 12 in both experiments; their sera were analyzed and the trabecular and cortical bone of distal femurs processed to determine calcium (Ca) and hydroxyproline content and dry weight. PTH and indomethacin had no significant effect on serum Ca, phosphate, alkaline phosphatase, urea nitrogen and creatinine, or systemic and long-bone linear growth. In rats treated with PTH alone or in combination with indomethacin, bone Ca of distal femurs increased by 28-44%; dry weight by 29-41%, and hydroxyproline by 17-45%. Indomethacin alone had no effect on bone growth. Since indomethacin did not block the anabolic effect of hPTH 1-34, we concluded that the anabolic effect of PGH in vivo was unlikely to be mediated by prostaglandins.

Original languageEnglish
Pages (from-to)206-211
Number of pages6
JournalCalcified Tissue International
Volume40
Issue number4
DOIs
Publication statusPublished - Jul 1987

Fingerprint

Anabolic Agents
Parathyroid Hormone
Indomethacin
Bone and Bones
Teriparatide
Dinoprostone
Bone Development
Hydroxyproline
Femur
Calcium
Weights and Measures
Subcutaneous Injections
Serum
Osteogenesis
Prostaglandins
Alkaline Phosphatase
Sprague Dawley Rats
Urea
Creatinine
Nitrogen

Keywords

  • Bone Ca
  • hPTH 1-34
  • Indomethacin
  • Parathyroid hormone
  • Prostaglandin

ASJC Scopus subject areas

  • Endocrinology
  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats. / Gera, I.; Hock, J. M.; Gunness-Hey, M.; Fonseca, J.; Raisz, L. G.

In: Calcified Tissue International, Vol. 40, No. 4, 07.1987, p. 206-211.

Research output: Contribution to journalArticle

Gera, I. ; Hock, J. M. ; Gunness-Hey, M. ; Fonseca, J. ; Raisz, L. G. / Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats. In: Calcified Tissue International. 1987 ; Vol. 40, No. 4. pp. 206-211.
@article{bdacf2d359be407baeb9c7584de3e8db,
title = "Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats",
abstract = "Chronic administration of parathyroid hormone, hPTH 1-34, increased bone mass in normocalcemic, young rats [6]. Since PTH can stimulate prostaglandin E2 (PGE2) production in bone in vitro, and since PGE2 can stimulate bone formation, the anabolic effect of PTH could be mediated by PGE2. To test this hypothesis, experiments were done to determine if indomethacin, which blocks endogeneous PG production, would inhibit the anabolic response of bone to PTH. In the first experiment, male Sprague-Dawley rats, 70-100 g, in groups of five, were treated for 12 days with either hPTH 1-34, 8 μg/100g/day; PTH vehicle; indomethacin, 2 mg/kg/day; or a combination of PTH and indomethacin. In the second experiment, groups of 6 rats each were given vehicle or hPTH 1-34, 8 μg/100g/day, in combination with indomethacin, 0, 1, 2, or 4 mg/kg/day. Subcutaneous injections of PTH were given once daily and indomethacin was given orally in divided doses, twice a day. Rats were killed on day 12 in both experiments; their sera were analyzed and the trabecular and cortical bone of distal femurs processed to determine calcium (Ca) and hydroxyproline content and dry weight. PTH and indomethacin had no significant effect on serum Ca, phosphate, alkaline phosphatase, urea nitrogen and creatinine, or systemic and long-bone linear growth. In rats treated with PTH alone or in combination with indomethacin, bone Ca of distal femurs increased by 28-44{\%}; dry weight by 29-41{\%}, and hydroxyproline by 17-45{\%}. Indomethacin alone had no effect on bone growth. Since indomethacin did not block the anabolic effect of hPTH 1-34, we concluded that the anabolic effect of PGH in vivo was unlikely to be mediated by prostaglandins.",
keywords = "Bone Ca, hPTH 1-34, Indomethacin, Parathyroid hormone, Prostaglandin",
author = "I. Gera and Hock, {J. M.} and M. Gunness-Hey and J. Fonseca and Raisz, {L. G.}",
year = "1987",
month = "7",
doi = "10.1007/BF02556623",
language = "English",
volume = "40",
pages = "206--211",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Indomethacin does not inhibit the anabolic effect of parathyroid hormone on the long bones of rats

AU - Gera, I.

AU - Hock, J. M.

AU - Gunness-Hey, M.

AU - Fonseca, J.

AU - Raisz, L. G.

PY - 1987/7

Y1 - 1987/7

N2 - Chronic administration of parathyroid hormone, hPTH 1-34, increased bone mass in normocalcemic, young rats [6]. Since PTH can stimulate prostaglandin E2 (PGE2) production in bone in vitro, and since PGE2 can stimulate bone formation, the anabolic effect of PTH could be mediated by PGE2. To test this hypothesis, experiments were done to determine if indomethacin, which blocks endogeneous PG production, would inhibit the anabolic response of bone to PTH. In the first experiment, male Sprague-Dawley rats, 70-100 g, in groups of five, were treated for 12 days with either hPTH 1-34, 8 μg/100g/day; PTH vehicle; indomethacin, 2 mg/kg/day; or a combination of PTH and indomethacin. In the second experiment, groups of 6 rats each were given vehicle or hPTH 1-34, 8 μg/100g/day, in combination with indomethacin, 0, 1, 2, or 4 mg/kg/day. Subcutaneous injections of PTH were given once daily and indomethacin was given orally in divided doses, twice a day. Rats were killed on day 12 in both experiments; their sera were analyzed and the trabecular and cortical bone of distal femurs processed to determine calcium (Ca) and hydroxyproline content and dry weight. PTH and indomethacin had no significant effect on serum Ca, phosphate, alkaline phosphatase, urea nitrogen and creatinine, or systemic and long-bone linear growth. In rats treated with PTH alone or in combination with indomethacin, bone Ca of distal femurs increased by 28-44%; dry weight by 29-41%, and hydroxyproline by 17-45%. Indomethacin alone had no effect on bone growth. Since indomethacin did not block the anabolic effect of hPTH 1-34, we concluded that the anabolic effect of PGH in vivo was unlikely to be mediated by prostaglandins.

AB - Chronic administration of parathyroid hormone, hPTH 1-34, increased bone mass in normocalcemic, young rats [6]. Since PTH can stimulate prostaglandin E2 (PGE2) production in bone in vitro, and since PGE2 can stimulate bone formation, the anabolic effect of PTH could be mediated by PGE2. To test this hypothesis, experiments were done to determine if indomethacin, which blocks endogeneous PG production, would inhibit the anabolic response of bone to PTH. In the first experiment, male Sprague-Dawley rats, 70-100 g, in groups of five, were treated for 12 days with either hPTH 1-34, 8 μg/100g/day; PTH vehicle; indomethacin, 2 mg/kg/day; or a combination of PTH and indomethacin. In the second experiment, groups of 6 rats each were given vehicle or hPTH 1-34, 8 μg/100g/day, in combination with indomethacin, 0, 1, 2, or 4 mg/kg/day. Subcutaneous injections of PTH were given once daily and indomethacin was given orally in divided doses, twice a day. Rats were killed on day 12 in both experiments; their sera were analyzed and the trabecular and cortical bone of distal femurs processed to determine calcium (Ca) and hydroxyproline content and dry weight. PTH and indomethacin had no significant effect on serum Ca, phosphate, alkaline phosphatase, urea nitrogen and creatinine, or systemic and long-bone linear growth. In rats treated with PTH alone or in combination with indomethacin, bone Ca of distal femurs increased by 28-44%; dry weight by 29-41%, and hydroxyproline by 17-45%. Indomethacin alone had no effect on bone growth. Since indomethacin did not block the anabolic effect of hPTH 1-34, we concluded that the anabolic effect of PGH in vivo was unlikely to be mediated by prostaglandins.

KW - Bone Ca

KW - hPTH 1-34

KW - Indomethacin

KW - Parathyroid hormone

KW - Prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=0023488473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023488473&partnerID=8YFLogxK

U2 - 10.1007/BF02556623

DO - 10.1007/BF02556623

M3 - Article

VL - 40

SP - 206

EP - 211

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 4

ER -